Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Venkata Sesha Sai Abhinav Ayyadevara, Gerald Wertheim, John Chukinas, Joseph Loftus, Sung June Lee, Anil Kumar, Srividya Swaminathan, Rahul S Bhansali, Wayne Childers, Huimin Geng, Thomas A Milne, Xianxin Hua, Kathrin M. Bernt, Thierry Besson, Junwei Shi, John D. Crispino, Martin P Carroll, Sarah K. Tasian, Christian Hurtz

Blood (2024) 144 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2024-206134

Published: 2024

Journal Articles

Targeting the SWI/SNF Chromatin Remodeling Complex Subunit SMARCA4 in ALL

Venkata Sesha Sai Abhinav Ayyadevara, Ashley Paik, Ria Perencsik, Monika Toma, Tomasz Skorski, Rozbeh Jafari, Gerald Wertheim, Huimin Geng, Christian Hurtz

Blood (2024) 144 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2024-205936

Published: 2024

Journal Articles

Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML

Jeremy Grenier, Sarah K. Tasian, Elliot Stieglitz, Zied Abdullaev, Gerald Wertheim, Marilyn M. Li, Charles A Phillips

Blood (2024) 144 (Supplement 1): 6739.

https://doi.org/10.1182/blood-2024-203951

Published: 2024

Journal Articles

Cancer Predisposition Genetic Testing Among Children with Hematologic Malignancies

Blood (2023) 142 (Supplement 1): 1458.

https://doi.org/10.1182/blood-2023-180008

Published: 2023

Journal Articles

Real-World Performance of 2022 Revised World Health Organization (WHO) Criteria for Mixed Phenotype Acute Leukemia (MPAL) B/Myeloid Defined Only By Isolated MPO Expression (isoMPO)

Alexandra E. Kovach, Sunil S. Raikar, Jemily Malvar, Matthew J. Oberley, Gerald Wertheim, Karen R. Rabin, Jyotinder N. Punia, Alix Seif, Reuven J. Schore, Dragos C. Luca, Terri L. Guinipero, William G. Woods, Viviane Cahen, Yueh-Yun Chi, Maurice R.G. O'Gorman, Brent L. Wood, Etan Orgel

Blood (2023) 142 (Supplement 1): 1467.

https://doi.org/10.1182/blood-2023-174110

Published: 2023

Journal Articles

The Mevalonate Pathway Is a Therapeutic Target in TP53 Mutant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 408.

https://doi.org/10.1182/blood-2023-185059

Published: 2023

Journal Articles

Transcriptomic without Clinical Response to Menin Inhibition As a Mechanism of Upfront Resistance in Samples from Mutliply Relapsed Patients with KMT2A-Rearranged Leukemia

Leila Mahdavi, Haley Goodrow, Hongbo Xie, Alexandra Lenard, Fatemeh Alikarami, Simone Stefanie Riedel, Sarah K. Tasian, Gerald Wertheim, Sarah Skuli, Martin Carroll, Jerry McGeehan, Kathrin M. Bernt

Blood (2023) 142 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2023-180967

Published: 2023

Journal Articles

A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders

Joshua D Brandstadter, Angelina De Martin, Mechthild Lϋetge, Antonio Ferreira, Brian T. Gaudette, Michael Gonzalez, Yves Stanossek, Edward Camiolo, Gerald Wertheim, David Allman, David C Fajgenbaum, Jon C. Aster, Burkhard Ludewig, Ivan Maillard

Blood (2022) 140 (Supplement 1): 3562–3563.

https://doi.org/10.1182/blood-2022-159835

Published: 2022

Journal Articles

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Caroline Diorio, Tiffaney L. Vincent, Tori Fuller, Rawan Shraim, Tina Glisovic-Aplenc, Theresa Ryan, Kimberly Veliz, Haley Newman, Gerald Wertheim, Hamid Bassiri, Annette Vu, Michael Hogarty, Carl H June, Stephan A. Grupp, Sarah K Tasian, Richard Aplenc, Saar Gill, David T. Teachey

Blood (2022) 140 (Supplement 1): 10285–10286.

https://doi.org/10.1182/blood-2022-167893

Published: 2022

Journal Articles

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Blood (2022) 140 (Supplement 1): 2376–2377.

https://doi.org/10.1182/blood-2022-168139

Published: 2022

Journal Articles

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

V. S. S. Abhinav Ayyadevara, Gerald Wertheim, John Chukinas, Joseph Patrick Loftus, Sung June Lee, Anil Kumar, Rahul S. Bhansali, Srividya Swaminathan, Thierry Besson, Junwei Shi, John D. Crispino, Sarah K Tasian, Martin P. Carroll, Christian Hurtz

Blood (2022) 140 (Supplement 1): 3486–3488.

https://doi.org/10.1182/blood-2022-162782

Published: 2022

Journal Articles

Targeting the Mevalonate Pathway in the Mitochondria-Dependent Chemotherapy Resistance of TP53 Mutant Acute Myeloid Leukemia

Sarah Skuli, A'Ishah Bakayoko, Bryan Manning, Gerald Wertheim, Jimmy Xu, Eva Nee, Lorelai Mesaros, Ryan Hausler, Manuela Lavorato, Eiko Ogiso, Marni Falk, Kara N. Maxwell, Nicolas Skuli, Clementina Mesaros, Martin P. Carroll

Blood (2022) 140 (Supplement 1): 8791–8792.

https://doi.org/10.1182/blood-2022-165660

Published: 2022

Journal Articles

FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation

Pamela J. Sung, Simone Sidoli, Simone S. Riedel, Katarzyna Kulej, Hongbo Xie, Bryan Manning, Daniel Tsai, Gerald Wertheim, Benjamin A. Garcia, Sara E. Meyer, Kathrin M. Bernt, Martin P. Carroll

Blood (2021) 138 (Supplement 1): 785.

https://doi.org/10.1182/blood-2021-147313

Published: 2021

Journal Articles

Standardization in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL): Semiquantitative, Universally Applicable Flow Cytometric Criteria for Immunophenotypic Lineage Assignment and Isolated MPO

Alexandra E. Kovach, Sunil S. Raikar, Matthew J. Oberley, Gerald Wertheim, Karen R Rabin, Jyotinder N. Punia, Alix E. Seif, Reuven J Schore, Dragos C. Luca, Terri Guinipero, William G Woods, Viviane Cahen, Maurice R.G. O'Gorman, Etan Orgel, Brent L. Wood

Blood (2021) 138 (Supplement 1): 4475.

https://doi.org/10.1182/blood-2021-154295

Published: 2021

Journal Articles

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Christian Hurtz, Gerald Wertheim, John Chukinas, Joseph Patrick Loftus, Sung June Lee, Anil Kumar, Rahul S. Bhansali, Srividya Swaminathan, Thierry Besson, Junwei Shi, John D. Crispino, Sarah K Tasian, Martin P. Carroll

Blood (2021) 138 (Supplement 1): 506.

https://doi.org/10.1182/blood-2021-144476

Published: 2021

Journal Articles

Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL

Asen Bagashev, Joseph Patrick Loftus, Colin Wakefield, Gerald Wertheim, Christian Hurtz, Martin P. Carroll, Kimberly Stegmaier, Yana Pikman, Sarah K Tasian

Blood (2021) 138 (Supplement 1): 705.

https://doi.org/10.1182/blood-2021-148671

Published: 2021

Journal Articles

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

Blood (2021) 138 (Supplement 1): 805.

https://doi.org/10.1182/blood-2021-148663

Published: 2021

Journal Articles

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Martin P. Carroll, MD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, MDPhD, Sung June Lee, BA, Anil Kumar, PhD, Anne Lehman, Joseph Patrick Loftus, BS, Grace Jeschke, PhD, John D. Crispino, PhD, Thierry Besson, PhD, Junwei Shi, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141258

Published: 2020

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Zhigang Cai, PhD, Baskar Ramdas, PhD, Jonathan Kotzin, Martin P. Carroll, MD, Gerald Wertheim, MD, PhD, Adam Williams, Jorge Henao-Mejia, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 915.

https://doi.org/10.1182/blood-2019-130653

Published: 2019

NARROW

KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Targeting the SWI/SNF Chromatin Remodeling Complex Subunit SMARCA4 in ALL

Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML

Cancer Predisposition Genetic Testing Among Children with Hematologic Malignancies

Real-World Performance of 2022 Revised World Health Organization (WHO) Criteria for Mixed Phenotype Acute Leukemia (MPAL) B/Myeloid Defined Only By Isolated MPO Expression (isoMPO)

The Mevalonate Pathway Is a Therapeutic Target in TP53 Mutant Acute Myeloid Leukemia

Transcriptomic without Clinical Response to Menin Inhibition As a Mechanism of Upfront Resistance in Samples from Mutliply Relapsed Patients with KMT2A-Rearranged Leukemia

A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Targeting the Mevalonate Pathway in the Mitochondria-Dependent Chemotherapy Resistance of TP53 Mutant Acute Myeloid Leukemia

FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation

Standardization in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL): Semiquantitative, Universally Applicable Flow Cytometric Criteria for Immunophenotypic Lineage Assignment and Isolated MPO

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only